Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IZ9O
|
|||
| Former ID |
DNC008414
|
|||
| Drug Name |
4-dehydroxyriccardin C
|
|||
| Synonyms |
4-dehydroxyriccardin C; Riccardin C derivative, 20d; CHEMBL411246; BDBM23851; 2',4-(Ethylene-1,4-phenylene-oxy-1,3-phenylene-ethylene)-1,1'-biphenyl-2,4'-diol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H24O3
|
|||
| Canonical SMILES |
C1CC2=C(C=CC(=C2)O)C3=C(C=C(CCC4=CC(=CC=C4)OC5=CC=C1C=C5)C=C3)O
|
|||
| InChI |
1S/C28H24O3/c29-23-11-15-26-22(18-23)10-6-19-7-12-24(13-8-19)31-25-3-1-2-20(16-25)4-5-21-9-14-27(26)28(30)17-21/h1-3,7-9,11-18,29-30H,4-6,10H2
|
|||
| InChIKey |
ZCEPVFMKRVLFDX-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Inhibitor | [1] |
| Oxysterols receptor LXR-beta (NR1H2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | PPAR signaling pathway | |||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Hepatitis C | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | SREBP signalling | |||
| Nuclear Receptors | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | ||||
| PPAR Alpha Pathway | ||||
| Liver X Receptor Pathway | ||||
| Adipogenesis | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.